One of the synergistic aspects of the current Program Project is that all of the individual projects will evaluate some aspect of their research questions in several common models, e.g., intracardiac and intratibial injection of tumor cells. Having common animal models allows us to rapidly translate findings from one project to another project. Due to the unique nature of bone compared to soft tissues, many models of bone metastasis are challenging and require special expertise. The Animal Core has provided extensive service to the Program in the previous grant cycle. The goal of the Animal Core, which has rated Superior, in previous reviews, is to continue to provide investigators of each project with assistance in the conduct of research involving animals including establishment of unique animal models (e.g., vertebral body implants known as vossicles), intracardiac and intratibial injection, in vivo and ex vivo tumor imaging and miscellaneous animal procedures. The core has been very successful achieving its goals and has always rated Superior in reviews. To continue to accomplish support of the Program the Animal Core has the following Aims:
Aim 1. Creating and assessing animal models to be used for the projects. In addition to routine animal modeling, we will facilitate use of animal models unique to bone metastasis research or that are challenging. For example, implantation of vertebrae to create vossicles, intratibial injections, intracardiac injections and orthotopic implants will be performed by the Animal Core.
Aim 2. Assisting with animal experiments. Core personnel will coordinate and assist or instruct in the performance of standardized procedures such as in vivo imaging, intracardiac injections, compound injections, anesthesia, etc.
Aim 3. Imaging animals. The core will assist with imaging including faxitron radiographs, bioluminescent imaging, bone density (DEXA) scanning and ?CT.
Aim 4. Providing expertise in use of animal models and interpretation of data from these animals. Dr. Evan Keller, a Board-certified veterinary oncologist and Dr. Jill Keller, a Board- certified laboratory animal veterinarian, will provide expertise in interpretation of animal models as needed.
Aim 5. Ensuring all animal experiments have appropriate animal compliance. In collaboration with Administrative core, we will ensure that all experiments are performed under appropriate institute approval

Public Health Relevance

Bone metastases are a serious and frequent clinical complication of prostate cancer. This core will provide animal models to help identify mechanisms and targets to attack this important aspect of prostate cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176

Showing the most recent 10 out of 228 publications